the preferred active compounds of the present invention are in an ionized , salt form or as the free base of the pharmaceutically acceptable salts thereof ( provided , for the aerosol or pump spray compositions , they are soluble in the spray solvent ). these compounds are soluble in the non - polar solvents of the invention at useful concentrations or can be prepared as pastes at useful concentrations . these concentrations may be less than the standard accepted dose for these compounds since there is enhanced absorption of the compounds through the oral mucosa . this aspect of the invention is especially important when there is a large ( 40 - 99 . 99 %) first pass effect . as propellants for the non polar sprays , propane , n - butane , iso - butane , n - pentane , iso - pentane , and neo - pentane , and mixtures thereof may be used . n - butane and iso - butane , as single gases , are the preferred propellants . it is permissible for the propellant to have a water content of no more than 0 . 2 %, typically 0 . 1 - 0 . 2 %. all percentages herein are by weight unless otherwise indicated . it is also preferable that the propellant be synthetically produced to minimize the presence of contaminants which are harmful to the active compounds . these contaminants include oxidizing agents , reducing agents , lewis acids or bases , and water . the concentration of each of these should be less than 0 . 1 %, except that water may be as high as 0 . 2 %. suitable non - polar solvents for the capsules and the non - polar sprays include ( c 2 - c 24 ) fatty acid ( c 2 - c 6 ) esters , c 7 - c 18 hydrocarbon , c 2 - c 6 alkanoyl esters , and the triglycerides of the corresponding acids . when the capsule fill is a paste , other liquid components may be used instead of the above low molecular weight solvents . these include soya oil , corn oil , other vegetable oils . as solvents for the polar capsules or sprays there may be used low molecular weight polyethyleneglycols ( peg ) of 400 - 1000 mw ( preferably 400 - 600 ), low molecular weight ( c 2 - c 8 ) mono and polyols and alcohols of c 7 - c 18 linear or branch chain hydrocarbons , glycerin may also be present and water may also be used in the sprays , but only in limited amount in the capsules . it is expected that some glycerin and water used to make the gelatin shell will migrate from the shell to the fill during the curing of the shell . likewise , there may be some migration of components from the fill to the shell during curing and even throughout the shelf - life of the capsule . therefore , the values given herein are for the compositions as prepared , it being within the scope of the invention that minor variations will occur . the preferred flavoring agents are synthetic or natural oil of peppermint , oil of spearmint , citrus oil , fruit flavors , sweeteners ( sugars , aspartame , saccharin , etc . ), and combinations thereof . the active substances include the active compounds selected from the group consisting of cyclosporine , sermorelin , octreotide acetate , calcitonin - salmon , insulin lispro , sumatriptan succinate , clozepine , cyclobenzaprine , dexfenfluramine hydrochloride , glyburide , zidovudine , erythromycin , ciprofloxacin , ondansetron hydrochloride , dimenhydrinate , cimetidine hydrochloride , famotidine , phenyloin sodium , phenyloin , carboprost thromethamine , carboprost , diphenhydramine hydrochloride , isoproterenol hydrochloride , terbutaline sulfate , terbutaline , theophylline , albuterol sulfate and neutraceuticals , that is to say nutrients with pharmacological action such as but not limited to carnitine , valerian , echinacea , and the like . in another embodiment , the active compound is a cholesterol - lowering agent , aldosterone antagonist , triglyceride - lowering agent , leukotriene receptor antagonist , immunomodulator or immunogen , glucose production inhibitor , agent for treatment of type ii diabetes , bone resorption inhibitor , calcium absorption enhancer , insulin enhancing agent , insulin sensitizer , cytokine , metabolic regulator , leukotriene receptor antagonist , mast cell mediator , eosinophil and / or mast cell antagonist , glycolipid , glycoprotein , anti - inflammatory drug , anti - obesity drug , cox ( cyclooxygenase ) and / or lo ( lipoxygenase ) inhibitor , or a mixture thereof . in one embodiment the active compound is a cholesterol - lowering agent . suitable cholesterol - lowering agents for use in the buccal sprays of the invention include , but are not limited to , atorvastatin , benzofibrate , bezafibrate , cerivastatin , cholestyramine , ciprofibrate , clofibrate , colesevelam , colestipol , ezetimibe , fluvastatin , gemfibrozil , lovastatin , niacin / lovastatin , pravastatin , probucol , rosuvastatin , and simvastatin . in one embodiment the active compound is an aldosterone antagonist . a suitable aldosterone antagonist for use in the buccal sprays of the invention includes , but is not limited to , spironolactone . in one embodiment the active compound is a triglyceride - lowering agent . a suitable triglyceride - lowering agent for use in the buccal sprays of the invention includes , but is not limited to , fenofibrate . in one embodiment the active compound is a leukotriene receptor antagonist . suitable leukotriene receptor antagonist for use in the buccal sprays of the invention include , but are not limited to , ramatroban , zariflukast , and montelukast . in one embodiment the active compound is a immunomodulator or immunogen . suitable immunomodulators or immunogen receptors for use in the buccal sprays of the invention include , but are not limited to , interferon beta 1a , interferon beta 1b in one embodiment the active compound is a glucose production inhibitor . suitable glucose production inhibitors for use in the buccal sprays of the invention include , but are not limited to , acarbose , acetohexamide , chlorpropamide , glipizide , glyburide , metformin , miglitol , nateglinide , pioglitazone , rosiglitazone , tolbutamide , and tolazamide . in one embodiment the active compound is an agent for treatment of type ii diabetes . suitable agents for treatment of type ii diabetes for use in the buccal sprays of the invention include , but are not limited to , acarbose , acetohexamide , chlorpropamide , glipizide , glyburide , metformin , miglitol , nateglinide , rosiglitazone , tolbutamide , and tolazamide . in one embodiment the active compound is a bone resorption inhibitor . suitable bone resorption inhibitors for use in the buccal sprays of the invention include , but are not limited to , alendronate , ibandronate , minodronate , risedronate , etidronate , tiludronate , and mixtures thereof . in one embodiment the active compound is a calcium absorption enhancer . suitable calcium absorption enhancers for use in the buccal sprays of the invention include , but are not limited to , alfacalcidol and calcitriol . in one embodiment the active compound is an insulin enhancing agent . suitable insulin enhancing agents for use in the buccal sprays of the invention include , but are not limited to , acamprosate , miglitol , troglitazone , chlorpropamide , glimepiride , glipizide , glyburide , and repaglinide . in one embodiment the active compound is an insulin sensitizer . a suitable insulin sensitizer for use in the buccal sprays of the invention includes , but is not limited to , is brl 49653 . in one embodiment the active compound is a cytokine . suitable cytokines for use in the buccal sprays of the invention include , but are not limited to , darbepoetin alfa , epoetin alpha , erythropoietin , and nesp . in one embodiment the active compound is a metabolic regulator . suitable metabolic regulators for use in the buccal sprays of the invention include , but are not limited to , allopurinol and oxypurinol . in one embodiment the active compound is a leukotriene receptor antagonist . suitable leukotriene receptor antagonists for use in the buccal sprays of the invention include , but are not limited to , montelukast , zafirlukast , and ibudilast . in one embodiment the active compound is a mast cell mediator . suitable mast cell mediators for use in the buccal sprays of the invention include , but are not limited to , ketotifen and cromolyn . in one embodiment the active compound is an eosinophil and / or mast cell antagonist . a suitable eosinophil and / or mast cell antagonists for use in the buccal sprays of the invention includes , but is not limited to , is nedocromil . in one embodiment the active compound is a glycolipid . suitable glycolipids for use in the buccal sprays of the invention include , but are not limited to , imigulcerase , vancomycin , vevesca ( ogt 918 ), and gmk vaccine . in one embodiment the active compound is a glycoprotein . suitable glycoproteins for use in the buccal sprays of the invention include , but are not limited to , staphvax , bimosiamose ( tbc1269 ), gcs - 100 , and heparin . in one embodiment the active compound is an anti - inflammatory drug . suitable anti - inflammatory drugs for use in the buccal sprays of the invention include , but are not limited to , alosetron , anakinra , beclomethasone , betamethasone , budesonide , clobetasol , celecoxib , cromolyn , desoximetasone , dexamethasone , epinastic , etanercept , etoricoxib , flunisolide , fluocinonide , fluticasone , formoterol , hydrocortisone , hydroxychloroquine , ibudilast , ketotifen , meloxicam , mesalamine , methotrexate , methylprednisolone , mometasone , montelukast , nedocromil , olsalazine , prednisone , ramatroban , rofecoxib , salsalate , terbutaline , triamcinolone , valdecoxib , and zafirlukast . in one embodiment the active compound is an anti - obesity drug . suitable anti - obesity drugs for use in the buccal sprays of the invention include , but are not limited to , dexedrine , diethylpropion , mazindol , oleoyl - estrone , phentermine , phendimetrazine , and sibutramine . in one embodiment the active compound is a cox and / or lo inhibitor . a suitable cox and / or lo inhibitor for use in the buccal sprays of the invention includes , but is not limited to , is ml - 3000 . the formulations of the present invention comprise an active compound or a pharmaceutically acceptable salt thereof . the term apharmaceutically acceptable salts ≅ refers to salts prepared from pharmaceutically acceptable non - toxic acids or bases including organic and inorganic acids or bases . when an active compound of the present invention is acidic , salts may be prepared from pharmaceutically acceptable non - toxic bases . salts derived from all stable forms of inorganic bases include aluminum , ammonium , calcium , copper , iron , lithium , magnesium , manganese , potassium , sodium , zinc , etc . particularly preferred are the ammonium , calcium , magnesium , potassium , and sodium salts . salts derived from pharmaceutically acceptable organic non - toxic bases include salts of primary , secondary , and tertiary amines , substituted amines including naturally occurring substituted amines , cyclic amines and basic ion - exchange resins such as arginine , betaine , caffeine , choline , n , n dibenzylethylenediamine , diethylamine , 2 - diethylaminoethanol , 2 - dimethylaminoethanol , ethanolamine , ethylenediamine , n - ethylmorpholine , n - ethylpiperidine , glucamine , glucosamine , histidine , isopropylamine , lysine , methyl - glucosamine , morpholine , piperazine , piperidine , polyamine resins , procaine , purine , theobromine , triethylamine , trimethylamine , tripropylamine , etc . when an active compound of the present invention is basic , salts may be prepared from pharmaceutically acceptable non - toxic acids . such acids include acetic , benzenesulfonic , benzoic , camphorsulfonic , citric , ethane - sulfonic , fumaric , gluconic , glutamic , hydrobromic , hydrochloric , isethionic , lactic , maleic , mandelic , methanesulfonic , mucic , nitric , pamoic , pantothenic , phosphoric , succinic , sulfuric , tartaric , p - toluenesulfonic , etc . particularly preferred are citric , hydrobromic , maleic , phosphoric , sulfuric , and tartaric acids . in the discussion of methods of treatment herein , reference to the active compounds is meant to also include the pharmaceutically acceptable salts thereof . while certain formulations are set forth herein , the actual amounts to be administered to the mammal or man in need of same are to be determined by the treating physician . the invention is further defined by reference to the following examples , which are intended to be illustrative and not limiting . the following are examples of certain classes . all values unless otherwise specified are in weight percent . cns active amines and their salts : including but not limited to tricyclic amines , gaba analogues , thiazides , phenothiazine derivatives , serotonin antagonists and serotonin reuptake inhibitors
buccal aerosol sprays or capsules using polar and non - polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa , resulting in fast onset of effect . the buccal polar compositions of the invention comprise formulation i : aqueous polar solvent , active compound , and optional flavoring agent ; formulation ii : aqueous polar solvent , active compound , optionally flavoring agent , and propellant ; formulation iii : non - polar solvent , active compound , and optional flavoring agent ; and formulation iv : non - polar solvent , active compound , optional flavoring agent , and propellant .